Source-grounded facts extracted from GeoVax Labs, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GeoVax Labs, Inc. entered into Inducement Letters with holders of existing warrants valued at aggregate gross proceeds of approximately $595,000 (effective 2026-05-07).
“On May 7, 2026, GeoVax Labs Inc. (the “Company”), entered into common stock warrant exercise inducement offer letters (the “Inducement Letters”) with holders (the “Holders”) of existing warrants to purchase shares of the Company’s common stock”
GeoVax Labs, Inc. reported the year ended December 31, 2025 results: revenue $2.5 million, net income $21.5 million, EPS $22.40 per share.
“Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024. Revenue : For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024.”
GeoVax Labs, Inc. entered into Purchase Agreement with the purchasers party thereto valued at approximately $865,000 (effective 2026-02-13).
“On February 13, 2026, GeoVax Labs, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of (i) 402,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 30,902 shares of Common Stock (the “Pre-Funded Warrant Shares”).”
GeoVax Labs, Inc.: Filed Certificate of Amendment for 1-for-25 reverse stock split (effective 2026-01-09).
“On January 9, 2026, GeoVax Labs, Inc. (the “Company” or “we”) filed a Certificate of Amendment to our Certificate of Incorporation effecting a 1-for-25 reverse stock split”
GeoVax Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until January 27, 2026 (the “Compliance Date”), to”
GeoVax Labs, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.